SynthesisPloS one2017
Diagnostic Value of Urine Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Acute Kidney Injury: A Meta-Analysis.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Pooled it
- The diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for acute kidney injury in adults: A PRISMA-compliant meta-analysis.Medicine · 2017Pooled it
- Development and validation of a machine-learning-based model for identification of genes associated with sepsis-associated acute kidney injury.Frontiers in genetics · 2025Article
- Article
- Prognostic Biomarkers and AKI: Potential to Enhance the Identification of Post-Operative Patients at Risk of Loss of Renal Function.Research and reports in urology · 2024Review
- IGFBP2 function as a novel biomarker for active lupus nephritis.Journal of molecular medicine (Berlin, Germany) · 2022Article
- Burn-Induced Acute Kidney Injury-Two-Lane Road: From Molecular to Clinical Aspects.International journal of molecular sciences · 2022Review
- Article
- Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma.Journal of Cancer · 2022Review
- Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury.Clinical proteomics · 2021Review
- Potential Prognostic Markers of Acute Kidney Injury in the Early Phase of Acute Pancreatitis.International journal of molecular sciences · 2019Review
- Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel.Critical care (London, England) · 2019Article
- Kidney Injury Biomarkers in an Academic Hospital Setting: Where Are We Now?The Clinical biochemist. Reviews · 2019Review
- Urinary TIMP2 and IGFBP7 Identifies High Risk Patients of Short-Term Progression from Mild and Moderate to Severe Acute Kidney Injury during Septic Shock: A Prospective Cohort Study.Disease markers · 2019Observational
- IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI.Oncotarget · 2018Article
- Mechanisms Underlying Increased TIMP2 and IGFBP7 Urinary Excretion in Experimental AKI.Journal of the American Society of Nephrology : JASN · 2018Article
- Diagnostic prediction of urinary [TIMP-2] x [IGFBP7] for acute kidney injury: A meta-analysis exploring detection time and cutoff levels.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein-7 (IGFBP7) are both involved in renal tubular epithelial cell cycle arrest in acute kidney injury (AKI). Several recent studies showed that urine TIMP-2 times IGFBP7 ([TIMP-2]*[IGFBP7]) is a promising biomarker to predict AKI.
methodsThe aim of this meta-analysis was to assess the diagnostic value of urine [TIMP-2]*[IGFBP7] for early diagnosis of AKI. Relevant studies were retrieved from the PubMed, EMBASE, and Cochrane Library databases. The sensitivity and specificity were determined, and summary receiver operating characteristic (SROC) curves were constructed.
resultsTen full-text prospective studies were included in this meta-analysis. The estimated sensitivity of urine [TIMP-2]*[IGFBP7] for the early diagnosis of AKI was 0.84 (95% CI = 0.80-0.88) and the specificity was 0.57 (95%CI = 0.55-0.60). The SROC analysis showed an area under the curve of 0.8813. LIMITATION: The limited number of included studies, small sample size, unpublished negative results and language limitation might have affected the evaluation.
conclusionUrine [TIMP-2]*[IGFBP7] is a promising candidate for early detection of AKI, especially in ruling-out AKI. However, the potential of this biomarker should be validated in larger studies with a broader spectrum of clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.